60 Degrees Pharmaceuticals Files 8-K Report
Ticker: SXTPW · Form: 8-K · Filed: Jul 16, 2024 · CIK: 1946563
| Field | Detail |
|---|---|
| Company | 60 Degrees Pharmaceuticals, Inc. (SXTPW) |
| Form Type | 8-K |
| Filed Date | Jul 16, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-k
TL;DR
60 Degrees Pharma filed an 8-K on 7/16/24, confirming corporate details and reporting status.
AI Summary
On July 16, 2024, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is a Delaware-incorporated entity with its principal executive offices located at 1025 Connecticut Avenue NW, Suite 1000, Washington, D.C. 20036. The report is a current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
This 8-K filing serves as an official notification to the SEC and investors about the company's current reporting status and corporate information.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain information about significant financial events, mergers, or executive changes.
Key Numbers
- 001-41719 — SEC File Number (Identifies the company's filing with the SEC.)
- 45-2406880 — IRS Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- 60 DEGREES PHARMACEUTICALS, INC. (company) — Registrant
- July 16, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 1025 Connecticut Avenue NW, Suite 1000 Washington , D.C . 20036 (address) — Registrant's principal executive office
- 001-41719 (company_id) — Commission File Number
FAQ
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is 60 DEGREES PHARMACEUTICALS, INC.
In which state is 60 Degrees Pharmaceuticals, Inc. incorporated?
The company is incorporated in Delaware.
What is the address of the registrant's principal executive office?
The principal executive office is located at 1025 Connecticut Avenue NW, Suite 1000, Washington, D.C. 20036.
What is the Commission File Number for 60 Degrees Pharmaceuticals, Inc.?
The Commission File Number is 001-41719.
On what date was the earliest event reported in this 8-K filing?
The date of the earliest event reported is July 16, 2024.
Filing Stats: 1,029 words · 4 min read · ~3 pages · Grade level 12.3 · Accepted 2024-07-16 17:28:43
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 SXTP The Nasdaq Stock Market LLC
Filing Documents
- ea0209525-8k_60degrees.htm (8-K) — 47KB
- 0001213900-24-061853.txt ( ) — 262KB
- sxtp-20240716.xsd (EX-101.SCH) — 4KB
- sxtp-20240716_def.xml (EX-101.DEF) — 26KB
- sxtp-20240716_lab.xml (EX-101.LAB) — 36KB
- sxtp-20240716_pre.xml (EX-101.PRE) — 25KB
- ea0209525-8k_60degrees_htm.xml (XML) — 6KB
07 Submission
Item 5.07 Submission of Matters to a Vote of Security Holders. On July 16, 2024, 60 Degrees Pharmaceuticals, Inc., a Delaware corporation (the "Company"), held its virtual 2024 Annual Stockholders Meeting (the "Meeting"). As of the close of business on May 17, 2024, the record date for the determination of stockholders entitled to vote at the Meeting, there were 12,206,116 shares of the Company's common stock, par value $0.0001 per share, issued and outstanding, with each share entitled to one vote on each proposal at the Meeting. At the Meeting, the combined holders of 6,329,996 shares of the voting stock entitled to notice of and to vote at the Meeting were represented in person or by proxy, representing approximately 51.86% of the outstanding voting shares, and thereby a quorum pursuant to the Delaware General Corporation Law and the amended and restated bylaws of the Company was present for the transaction of business at the Meeting. The final results for each of the matters considered at the Meeting were as follows: 1. Election of the five nominees to the Board of Directors of the Company : Name Votes For Votes Against Abstained Broker Non-Votes Geoffrey Dow 3,654,324 0 1,277,025 1,398,647 Charles Allen 3,635,622 0 1,295,727 1,398,647 Stephen Toovey 3,632,099 0 1,299,250 1,398,647 Cheryl Xu 3,623,825 0 1,307,524 1,398,647 Paul Field 3,639,320 0 1,292,029 1,398,647 Each director nominee was elected to serve as a director until the Company's 2025 annual meeting of stockholders, or until such person's successor is duly elected and qualified, or until such person's earlier resignation, death or removal. Due to the fact that directors are elected by a plurality of the votes cast, votes could only be cast in favor of or withheld from the nominees and thus votes against were not applicable. 2. Approval of an amendment to the 60 Degrees Pharmaceuticals, Inc. 2022 Equity Incentive Plan to increase the number of shares of com
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 16, 2024 60 DEGREES PHARMACEUTICALS, INC. By: /s/ Geoffrey Dow Name: Geoffrey Dow Title: Chief Executive Officer and President 3